visceral adipose tissue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-26. Numbers and descriptions here follow the published literature rather than marketing material.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
== Toxicity == Though few people come in contact with mendelevium, the International Commission on Radiological Protection has set annual exposure limits for the most stable isotope. For mendelevium-258, the ingestion limit was set at 9×105 becquerels (1 Bq = 1 decay per second). Given the half-life of this isotope, this is only 2.48 ng (nanograms). The inhalation limit is at 6000 Bq or 16.5 pg (picograms).
For services to Association Football and to Gender Equality. Rajwinder Singh. Principal Project Sponsor, Prison Infrastructure Team, Ministry of Justice. For Public Service. Dr. Sabesan Sithamparanathan, FREng. Founder and President, PervasID and Enterprise Fellow, Girton College, University of Cambridge. For services to Innovation Technology. David Alexander Smith. Departmental Records Officer and Chief Librarian, Department for Levelling Up, Housing and Communities. For services to Government Knowledge and Information Management. Marie Smith. Senior Officer, National Crime Agency. For services to Law Enforcement. Michelle Southern. Founder and Director, Street Paws. For services to Homeless People and their Pets. David Martin Sprackling. Lately Lawyer, Parliamentary Counsel, Office of the Parliamentary Counsel. For Public Service. Nicholas Stace. Chair, The Conduit Holding Company. For services to Consumers and to the Environment. Marc Howard Steene. Founder and Director, Outside In Art. For services to Art. Gavin Paul Stollar. Honorary Chair, Liberal Democrat Friends of Israel. For political service to the Jewish Community. Luigi Strinati. Delivery Director, HM Courts and Tribunals Service Wales. For Public Service. Lorraine Pfavayi Sunduza. Lately Chief Nurse, East London NHS Foundation Trust. For services to Mental and Community Health. Joanna Kathryn Swash. Group Chief Executive Officer, Moneypenny. For services to the Economy. Claire Louise Swift. Director of Social Responsibility, Making for Change. For services to the Rehabilitation of Prisoners.
== Chemistry == Chemically, Parmotrema perlatum contains atranorin and chloroatranorin, alongside a predominant stictic acid chemosyndrome that includes stictic as a major secondary metabolite and smaller amounts of constictic acid and other related substances. Testing the medulla (the inner layer beneath the upper cortex) with spot tests results in K+ (yellow), KC−, and P+ (orange) reactions. The cortical layer, in contrast, is K+ (yellow), KC−, and P−. The secondary metabolites of Parmotrema perlatum have been studied using gas chromatography–mass spectrometry (GC–MS) and liquid chromatography–mass spectrometry (LC–MS/MS). The lichen produces several notable compounds, including orcinol, atraric acid, benzoic acid, 2,4-dihydroxy-3,6-dimethyl-, methyl ester, and palmitic acid, methyl ester. GC–MS analysis revealed the presence of orcinol (63%) and atraric acid (21%) in the methanol extract, while benzoic acid was predominant in the chloroform extract. The hexane extract contained significant amounts of benzoic acid, 2,4-dihydroxy-3,6-dimethyl-, methyl ester (62%). A more recent study using liquid chromatography-electrospray ionization-mass spectrometry/mass spectrometry as an analysis technique tentatively identified a total of twenty-five lichen products, including 5 depsides, 12 depsidones, 2 diphenyl ethers, 1 aromatic considered as possible artifact, 1 dibenzofuran, 1 carbohydrate, 1 organic acid, and 2 undefined compounds.
Sources: en.wikipedia.org
=== Works cited === Edwards, Clive A.; Bohlen, P. J. (1996). Biology and Ecology of Earthworms. Springer Science & Business Media. ISBN 978-0-412-56160-3. Sims, Reginald William; Gerard, B (1985). Earthworms: Keys and Notes for the Identification and Study of the Species. London: Published for The Linnean Society of London and the Estuarine and Brackish-Water Sciences Association by E. J. Brill/Dr. W. Backhuys.
== History == COLD-PCR was originally described by Li et al. in a Nature Medicine paper published in 2008 from Mike Makrigiorgos's lab group at the Dana Farber Cancer Institute of Harvard Medical School. As summarized above, the technology has been used in a number of proof-of-principle experiments and medical research diagnostic experiments. Recently, the COLD-PCR technology has been licensed by Transgenomic, Inc. The licensing terms include the exclusive rights to commercialize the technology combined with Sanger sequencing. The plans are to develop commercial applications that will allow for rapid high-sensitivity detection of low-level somatic and mitochondrial DNA mutations.
Trump, long known before he took elective office for labeling his companies' properties and merchandise with his name or image, has controversially continued the practice in public life in his second presidential term, in some cases by altering existing names or images. Soon after the term began, Trump's portrait appeared on large banners hung from three federal buildings in Washington, D.C.; U.S. Sen. Adam Schiff (D.-Calif.) objected that the banners violated “a longstanding legal prohibition against the use of federal funds for propaganda and self-aggrandizement purposes.” Trump also promptly dismissed the Kennedy Center's board of trustees, then selected a replacement board, which voted in December to rename the center the Donald J. Trump and the John F. Kennedy Memorial Center for the Performing Arts; its signage was altered to reflect the new name. The change drew criticism from politicians in Congress, some of them in Trump's own party; House minority leader Hakeem Jeffries (D-N.Y.) declared that the board had “no authority to actually rename the Kennedy Center in the absence of legislative action,” and a federal judge later ordered that Trump's name be removed. The new board had appointed Trump himself to its chairmanship, a first for a president. That month, Trump also set his name on the U.S. Institute of Peace (USIP), renaming it the Donald J. Trump Institute of Peace, and its signage, too, was so altered. Trump had recently fired not only the USIP's board but its every employee, turning control of its headquarters over to the General Services Administration.
Sources: en.wikipedia.org
== Regulation == Transcriptional regulation of MMP-13 is tightly controlled due to its potent proteolytic capacity. There are several binding domains for various transcription factors including AP-1, PEA-3 and OSE-2 as well as a sequence with homology to a TGF-β inhibitory element (TIE). Moreover, several cytokines and growth factors have been demonstrated to affect Mmp13 gene expression, including parathyroid hormone, IGF-1, TGF-β, hepatocyte growth factor and many inflammatory cytokines such as IL-1α and IL-1β. The upstream regulatory region of the Mmp13 gene contains a number of transcription factor binding sites but it was recently discovered that there is a conserved forkhead response element (FHRE) consensus sequence for FOXO3a in the human, mouse and rat Mmp13 promoter. Endogenous FOXO3a activation results in marked upregulation of Mmp13 expression which is capable of promoting extracellular matrix degradation and apoptotic cell death.
β-Hydroxy β-methylbutyric acid (HMB), otherwise known as its conjugate base, β-hydroxy β-methylbutyrate, is a naturally produced substance in humans that is used as a dietary supplement and as an ingredient in certain medical foods that are intended to promote wound healing and provide nutritional support for people with muscle wasting due to cancer or HIV/AIDS. In healthy adults, supplementation with HMB has been shown to increase exercise-induced gains in muscle size, muscle strength, and lean body mass, reduce skeletal muscle damage from exercise, improve aerobic exercise performance, and expedite recovery from exercise; in trained and competitive athletes, evidence is mixed on whether it meaningfully augments resistance training–induced gains in lean mass and strength. Medical reviews and meta-analyses indicate that HMB supplementation also helps to preserve or increase lean body mass and muscle strength in individuals experiencing age-related muscle loss. HMB produces these effects in part by stimulating the production of proteins and inhibiting the breakdown of proteins in muscle tissue. No adverse effects from long-term use as a dietary supplement in adults have been found. The effects of HMB on human skeletal muscle were first discovered by Steven L. Nissen at Iowa State University in the mid-1990s. As of 2018, HMB has not been banned by the National Collegiate Athletic Association, World Anti-Doping Agency, or any other prominent national or international athletic organization.
These increases in coagulation factors may contribute to the development of stroke (see under § Side effects), but a precise association cannot be made at this stage. In a variety of clinical studies upon which FDA approval is based, Neumega showed effectivity in reducing thrombocytopenia in oncologic patients treated with myelosuppressant chemotherapeutic drugs as measured by significantly decreased need of platelet transfusions. Neumega is manufactured and sold by Wyeth. The drug is formulated in single-use vials containing 5 mg of oprelvekin (specific activity approximately 8 million units/mg) as a sterile, lyophilized powder. The FDA approved the drug in 1997.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.